WEBINAR INVITE: Previewing 2Q26 Large Cap Pharma Earnings - Expectations, Areas of Focus & What We Are Watching For

Research evidence excerpt

WEBINAR INVITE: Previewing 2Q26 Large Cap Pharma Earnings - Expectations, Areas of Focus & What We Are Watching For

Biotechnology July 9, 2026

Vamil Divan, M.D.

vamil.divan@guggenheimpartners.com WEBINAR INVITE: Previewing 2Q26 Large Cap

212 823 6543 Pharma Earnings - Expectations, Areas of Focus & Seamus Fernandez

seamus.fernandez@guggenheimpartners.com What We Are Watching For

617 859 4637

Edouard Mullarky, Ph.D. Please join us for a discussion with Seamus Fernandez and Vamil Divan, M.D., edouard.mullarky@guggenheimpartners.com

212 518 9579 facilitated by Healthcare Sales Specialist Whitney Wolfe. Seamus and Vamil will preview

Large Cap pharma earnings for 2Q 2026 across their combined large cap biopharma as

Daniel Krizay, Ph.D. well as their favorite ideas looking ahead to 2H 2026. The discussion will be moderated

daniel.krizay@guggenheimpartners.com by our Healthcare Sales Specialist Whitney Wolfe, and we will also field any inbound 212 823 6561

questions from investors.

Arseniy Shabashvili

arseniy.shabashvili@guggenheimpartners.com Potentially Impacted Companies: ABBV, ABSI, ACRS, AMGN, AMLX, ANIP, ARCT,

212 699 1971 ARQT, APGE, ASMB, AZN.LN, AVLN, BMY, ELDN, LLY, GENB, GSK.LN, GOSS, INSM,

Evan Wang IVA, JBIO, JNJ, MBX, MRK, MLYS, NAMS, NOVN-SWX, NOVO.B-CSE, RYTM, PCVX,

evan.wang@guggenheimpartners.com PFE, PROK, SAN-PAR, SCYX, SEPN, SGMT, GPCR, SVRA, TENX, TVTX, UNCY,

212 651 9756 VALN, VERA, VICO-SS, and others

Alana Lelo, Ph.D. Please Register HERE or contact your Guggenheim Sales Representative alana.lelo@guggenheimpartners.com

212 518 9955

Discussion Topics Colleen Garvey, Ph.D.

colleen.garvey@guggenheimpartners.com • Key takeaways from our work preparing for 2Q earnings and investor interactions ahead 617 859 4664

of the print

Zach Dunn, Ph.D.